老年髋部骨折患者术后骨质疏松治疗与再骨折风险:一项多中心回顾性队列研究
这项多中心回顾性队列研究纳入2010年1月至2024年12月在三家教学医院接受髋部骨折手术的65岁及以上患者,按是否接受指南推荐的骨质疏松治疗分组,经倾向性评分1:1匹配后1986例纳入主要分析。骨质疏松治疗组再骨折率显著低于未治疗组(22.6% vs 39.3%,p < 0.001),无再骨折生存期中位数更长(42 vs 26个月,p < 0.001),再骨折风险相对降低89%(HR = 0.11,95% CI: 0.07-0.18,p < 0.001);192例双侧髋部骨折患者中治疗组对侧骨折时间显著更长(40.5 vs 27.0个月,p < 0.001)。
要点
- 匹配后骨质疏松治疗组再骨折率22.6%,未治疗组39.3%(p < 0.001)。
- 骨质疏松治疗与再骨折风险相对降低89%相关(HR = 0.11,95% CI: 0.07-0.18,p < 0.001)。
- 双侧髋部骨折患者中治疗组对侧骨折时间40.5个月,未治疗组27.0个月(p < 0.001)。
核心结论
- 术后骨质疏松治疗显著降低再骨折风险并延迟对侧髋部骨折。
- 将此类治疗整合进常规术后护理对有效二级骨折预防至关重要。
研究设计与样本
- 多中心回顾性队列研究,纳入2010年1月至2024年12月在三家教学医院接受髋部骨折手术的65岁及以上患者。
- 按是否接受指南推荐的骨质疏松治疗分为治疗组与未治疗组,采用倾向性评分1:1匹配调整基线差异。
- 匹配后1986例纳入主要分析,另对192例双侧髋部骨折患者进行亚队列分析。
- 再骨折风险采用Kaplan-Meier分析和Cox回归评估。
主要发现
- 骨质疏松治疗组再骨折率为22.6%,未治疗组为39.3%(p < 0.001)。
- 骨质疏松治疗组无再骨折生存期中位数为42个月,未治疗组为26个月(p < 0.001)。
- 骨质疏松治疗与再骨折风险相对降低89%相关(HR = 0.11,95% CI: 0.07-0.18,p < 0.001)。
- 192例双侧髋部骨折患者中,治疗组对侧骨折时间为40.5个月,未治疗组为27.0个月(p < 0.001)。
临床怎么用
- 作者认为将术后骨质疏松治疗整合进常规术后护理对有效二级骨折预防至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This multicenter retrospective cohort study investigated the impact of guideline-concordant osteoporosis therapy on refracture risk and the timing of contralateral hip fractures in elderly patients following hip fracture surgery. PURPOSE: To evaluate whether osteoporosis treatment reduces the risk of subsequent fractures and prolongs the interval between initial and contralateral hip fractures in older adults. METHODS: Patients aged ≥ 65 years who underwent hip fracture surgery between January 2010 and December 2024 at three teaching hospitals were included. Patients were assigned to treatment or no treatment groups based on whether they received guideline-recommended osteoporosis therapy postoperatively. Propensity score matching (1:1) adjusted for baseline differences. Refracture risk was assessed using Kaplan-Meier analysis and Cox regression. A sub-cohort analysis examined the time to contralateral hip fracture in patients with bilateral fractures. RESULTS: After matching, 1986 patients were included in the primary analysis. The osteoporosis treatment group had a significantly lower refracture rate (22.6% vs. 39.3%, p < 0.001) and longer median refracture-free survival (42 vs. 26 months, p < 0.001). Osteoporosis therapy was associated with an 89% relative reduction in refracture risk (HR = 0.11, 95% CI: 0.07-0.18, p < 0.001). Among 192 patients with bilateral hip fractures, the time to contralateral fracture was significantly longer in the osteoporosis treatment group (40.5 vs. 27.0 months, p < 0.001). CONCLUSION: Postoperative osteoporosis therapy significantly lowers refracture risk and delays contralateral hip fracture. Integrating such treatment into routine postoperative care is essential for effective secondary fracture prevention.
引用
- Li X, Zhao Y, Cheng L, et al. Postoperative osteoporosis therapy and risk of re-fracture in elderly patients with hip fractures: a multicenter retrospective cohort study. Osteoporos Int. 2025. PMID: 41320716. doi:10.1007/s00198-025-07757-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。